BASFY Strengthens Acid Chlorides and Chloroformates Production

BASF SE BASFY has inaugurated its fully modernized plant for the production of acid chlorides and chloroformates (ACCF) at its Ludwigshafen Verbund site in Germany. The investment has been valued at a low three-digit million-euro amount. The step is expected to strengthen the company’s position by increasing production capacity and ensuring reliable supply all across the globe.

The investment includes a fundamental renewal of the production infrastructure for acid chlorides and chloroformates that will increase the capacity by approximately 30%. The ACCF products are widely used as building blocks in pharmaceuticals, crop protection products, organic peroxides, coatings, plastics and rubber applications.

The modernization also supports BASFY’s sustainability efforts as it is expected to reduce the portfolio’s product carbon footprint by an average of 19%, advancing Scope 3 emission reduction efforts for its customers. Since 2025, the company has produced its Ludwigshafen portfolio of around 25 acid chlorides and chloroformates using renewable electricity credits, including upstream raw material processes.

With increased capacity, improved infrastructure and lower product carbon footprints, this underscores BASFY’s focus on adapting more sustainable practices to achieve its broader goal of enabling its customers’ green transformation.

BASFY shares have gained 20.1% in the past year compared with the industry’s 1.6% rise.

Image Source: Zacks Investment Research

BASFY’s Zacks Rank & Key Picks

BASFY currently carries a Zacks Rank #3 (Hold)

Some better-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. NOPMF, Carpenter Technology Corporation CRS and Avient Corporation AVNT.

While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pinned at $1.4 per share, indicating a 185.71% year-over-year increase. NOPMF’sshares have gained 89.6% over the past year.

The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%.

The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.2 per share, indicating a 13.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’sshares have gained 16.9% over the past year.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research